Transparency Market Research (TMR) has come out with a latest report on the global hospital acquired infections treatment market. The report, while extensively capturing the trends in this buzzing market, sheds light on the underlying currents that drive competition. The barrage of generic drugs making way to the market have fired up the marketing teams of branded drugs as sales take a hit. While venturing into strategies to garner HCPs prescription loyalty is one, companies in the global hospital acquired infection treatment market are also resorting to conventional strategies like cost-reduction.
At the same time, companies in the global hospital acquired infection treatment market are upping the ante in rolling out generic formulations of legacy molecules to seize potential of untapped regions. Having said that, the competition in the global market for hospital acquired infections treatment is highly fragmented and has several players trying to gain an edge over the others. Some of prominent names include Abbott, Bayer AG, Pfizer, Inc., and Merck & Co. Inc.
In the recent TMR report, analysts cite that the future for the global market for hospital acquired infections treatment market looks bright. The possibilities of new drugs will keep the market buoyant and TMR analysts predict that the global hospital acquired infections market will reach US$ 36.1 bn by the end of 2024.
On the other hand, based on segments, the urinary tract sub-segment under infection type will propel growth in the market, say TMR analysts. Further, based on geography, Asia Pacific is expected to be the leading region in the coming years. The rising instances of hospital acquired infections in this region will surge demand for drugs in the global hospital acquired infection treatment market.
Rural and Urban Areas to Garner Growth
Hygiene and sanitation form the basis for hospital acquired infections. Having established that Asia Pacific will be the largest consumer of drugs in the global hospital acquired infections treatment market, it is important to understand the reasons behind it. A large portion of this geography is either under developed or is developing. Even the emerging and developed economies have a large rural population which is deprived of access to quality healthcare. As a result, the public healthcare segment is often burdened with hospital acquired infections while rendering treatment.
At the same time, the private establishments set up in urban areas too are subject to poor maintenance. With rising influx of patients who are predominantly migratory population, these hospitals are unable to manage the patient volume. This, often results in hospital acquired infections. These aspects will remain key for growth in the global hospital acquired infections market.
Technology and Improving Infrastructure to Impact Demand
While rural and urban areas will continue to remain at the fore of demand in the global hospital acquired infections treatment market, it is important for companies to keep updated about the latest technology and improving healthcare infrastructure. Most developing economies have realized the loss incurred through diseases burden and its impact on the GDP. To control this, policy makers are rolling out measures that improve quality of healthcare, both at the public and private level.
As these policies bear fruit, the incidence of hospital acquired infections will come down in the coming days. This will directly impact the demand for drugs in the global hospital acquired infections treatment market. However, varying conditions and evolution in microbes will open new opportunities for research in the global hospital acquired infections treatment market.
The study presented above is based on a Transparency Market Research report on “Hospital Acquired Infection Treatment Market (Infection Type - Urinary Tract Infections, Ventilator Associated Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infection, ENT Infections, Skin Infection, and Bone Infection; Treatment Type - Antibacterial, Antiviral, Antifungal Treatment, Antiparasitic, Antiprotozoal, and Anti-TB Treatment; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Store, and E-Commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
The global hospital acquired infections treatment market is segmented based on
- Urinary tract infections
- Ventilator associate pneumonia
- Blloodstream infections
- Surgical site infections
- Gastrointestinal infections
- ENT infections
- Skin infections
- Bone infections
- Hospital pharmacies
- Retail pharmacies
- Drug store
- North America
- United States
- The United Kingdom
- South Korea
- Latin America
- Middle East and Africa
- United Arab Emirates
- Saudi Arabia
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
7 of 10 large enterprizes view our ToC to take the right decision.View Report ToC